axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
Published 11 years ago • 948 plays • Length 11:26Download video MP4
Download video MP3
Similar videos
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
12:21
intorsect trial: second-line temsirolimus versus sorafenib in renal cell carcinoma
-
0:50
dr. viktor grünwald on dovitinib versus sorafenib in metastatic renal cell carcinoma
-
1:19
dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc
-
8:31
second-line angiogenesis inhibition in metastatic renal cell carcinoma
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
6:23
second-line treatment of metastatic renal cell carcinoma
-
7:07
selecting second-line agents in renal cell carcinoma
-
28:11
managing advanced renal cell carcinoma - quinn
-
7:09
second-line treatment selection in renal cell carcinoma
-
5:09
comparz trial and alternate sunitinib dosing schedule in metastatic renal cell carcinoma
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:38
dr. rini explains the axitinib integration process
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
0:43
dr. rini discusses the vegf targeted agent axitinib